Vertex Pharmaceuticals was the only bidder for Crinetics Pharmaceuticals in a contested process that still involved a substantial acquisition premium. The setup highlights how strategic assets in endocrine and peptide-adjacent pipelines can concentrate attention among remaining large buyers, even as deal competition appears limited. The move adds another acquisition layer to Vertex’s portfolio buildout.